Detection and monitoring of liver damage

1. A method of assessing the severity of non-alcoholic fatty liver disease in a subject, the method comprising:

obtaining a bodily sample from the subject, wherein the bodily sample is selected from the group consisting of blood, plasma, and serum;

measuring the level of caspase-3 generated cytokeratin-18 fragments which are cleaved at aspartic acid residue 396 in the bodily sample; and

correlating the level of caspase-3 generated cytokeratin-18 fragments which are cleaved at aspartic acid residue 396 with the severity of non-alcoholic fatty liver disease in the subject, wherein the higher the measured level of caspase-3 generated cytokeratin-18 fragments which are cleaved at aspartic acid residue 396 in the bodily sample compared to a predetermined value, the more severe the non-alcoholic fatty liver disease in the subject.

2. The method of claim 1 , the caspase-3 generated cytokeratin fragments being measured using an enzyme-linked immunosorbent assay (ELISA).

3. The method of claim 2 , the enzyme-linked immunosorbent assay measuring the level of caspase-3 generated cytokeratin-18 fragments in units per liter (U/L), wherein the higher the U/L of caspase-3 generated cytokeratin-18 fragments in the bodily sample the more severe the liver disease in the subject.

4. The method of claim 1 , wherein the higher the measured level of caspase-3 generated cytokeratin-18 fragments in the bodily sample compared to a predetermined value, the more likely the subject has nonalcoholic steatohepatitis (NASH) than steatosis.

5. The method of claim 1 , wherein the higher the measured level of caspase-3 generated cytokeratin-18 fragments in the bodily sample compared to a predetermined value, the more likely the subject has moderate or severe fibrosis than mild fibrosis.